This evidence highlights the potential of further investigating p11’s role in schizophrenia to enable a more comprehensive treatment approach—one that moves beyond D2R antagonism to address both core positive symptoms of schizophrenia and its associated neuropsychiatric disturbances. Here, S100A10 is linked to schizophrenia.